“We are excited about teaming up with CBL to fulfill a real need that up-to-now has impeded urine biomarker discovery efforts,” commented P. Shannon Pendergrast, Chief Science Officer at Ymir Genomics, LLC.
Cambridge, Massachusetts (PRWEB) October 28, 2015
Ymir Genomics has developed a novel and efficient platform for the isolation of Extra-cellular Vesicles (EVs) and/or Extra-cellular RNA from urine. This method works directly from whole urine samples and has been shown to work in samples stored for over 1 year at -80° C. The method even works on very dilute samples. EVs isolated by Ymir are intact and contain multiple exosomal/vesicle protein markers (i.e. CD9, Rab5, HSP70). RNA isolated by Ymir is suitable for qRT-PCR, RNA Array downstream analysis and is currently being evaluated for Next Generation Sequencing.
The Ymir Genomics Urine Extra-cellular Vesicle/RNA Isolation Service is now available to beta-testers. Users can send samples directly to Ymir Genomics and receive back either Extra-cellular vesicle or Extra-cellular RNA preps. Furthermore, Ymir Genomics has teamed up with respected contract research organization, Cambridge Biolabs (CBL) to offer downstream analysis of Extra-cellular RNA preps with qRT-PCR or miRNA microarrays. See http://www.ymirgenomics.com/ymir for more details.
“We are excited about teaming up with CBL to fulfill a real need that up-to-now has impeded urine biomarker discovery efforts,” commented P. Shannon Pendergrast, Chief Science Officer at Ymir Genomics, LLC. “With our technology and CBLs outstanding analysis this easily acquired biofluid is now more accessible to academic, clinical, and pharmaceutical researchers.”
“The isolation technology developed by Ymir Genomics is a great leap forward for exosome studies. We at Cambridge Biolabs are thrilled to expand our service offerings in conjunction with Ymir, and to contribute to advancements in biomarker research.” – Laura Holberger, Cambridge Site Manager at Cambridge Biolabs, LLC.
About Ymir Genomics:
Ymir Genomics LLC is a biotech start-up based at LabCentral in Cambridge, Massachusetts. The company is committed to providing researchers with the tools they need to create non-invasive diagnostic and prognostic assays from biofluids such as urine, CSF, and saliva. Ymir Genomics is also using these tools internally and through collaborations to search for urine biomarkers for cancer and diabetes.
About Cambridge Biolabs:
Cambridge Biolabs (http://www.cambridgebiolabs.com/) is a state-of-the art biotechnology incubator and contract research organization located in Cambridge MA. CRO Services include Assay Development, RT-qPCR, High-throughput Screening and RNAi. Attention to detail and responsive Customer Service are stressed for every project.